Nobiletin promotes antioxidant and anti-inflammatory responses and elicits protection against ischemic stroke in vivo

Brain Res. 2016 Apr 1:1636:130-141. doi: 10.1016/j.brainres.2016.02.013. Epub 2016 Feb 10.

Abstract

Background: Post-ischemic oxidative stress and inflammation play pivotal roles in the pathogenesis of ischemic stroke and may represent therapeutic targets. Nobiletin (NOB) has been reported to elicit a variety of biological effects through its anti-oxidant and anti-inflammatory properties. Our previous study has demonstrated the beneficial effect of NOB in ischemic stroke, but the underlying mechanisms remain poorly defined. We therefore further investigated the role of NOB in cerebral ischemia and its potential mechanisms.

Methods: Adult male Sprague-Dawley rats were randomly assigned to five groups: Sham (sham-operated+0.05% Tween-80), permanent middle cerebral artery occlusion (pMCAO+0.9% saline), Vehicle (pMCAO+0.05% Tween-80), NOB-L (pMCAO+NOB 10mg/kg) and NOB-H (pMCAO+NOB 25mg/kg) groups. Rats were pre-administered intraperitoneally once daily for 3 days prior to ischemia and then received once again immediately after surgery. Neurological deficit, brain edema and infarct volume were evaluated at 24h after stroke. Immunohistochemistry, western blot and RT-qPCR were used to detect the expression of Nrf2, HO-1, SOD1, NF-κB and MMP-9. SOD1, GSH and MDA were measured by spectrophotometer.

Results: Compared with Vehicle group, neurological deficits and brain edema were relieved in NOB-H group, infarct volume was lessened in both NOB-L and NOB-H groups (P<0.05). NOB significantly increased the expression of Nrf2, HO-1, SOD1 and GSH, while decreased the levels of NF-κB, MMP-9 and MDA (P<0.05).

Conclusion: NOB may have a neuroprotective effect on cerebral ischemia, and this protection may be through upregulating Nrf2, HO-1 and downregulating NF-κB expression.

Keywords: HO-1; Ischemic stroke; NF-κB; Neuroprotection; Nobiletin; Nrf2.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antioxidants* / therapeutic use
  • Brain Edema / drug therapy
  • Brain Edema / etiology
  • Brain Infarction / drug therapy
  • Brain Infarction / etiology
  • Disease Models, Animal
  • Dose-Response Relationship, Drug
  • Encephalitis* / drug therapy
  • Encephalitis* / etiology
  • Flavones* / therapeutic use
  • Functional Laterality
  • Gene Expression Regulation* / drug effects
  • Heme Oxygenase-1 / genetics
  • Heme Oxygenase-1 / metabolism
  • Infarction, Middle Cerebral Artery* / complications
  • Infarction, Middle Cerebral Artery* / drug therapy
  • Male
  • Matrix Metalloproteinase 9 / genetics
  • Matrix Metalloproteinase 9 / metabolism
  • NF-E2-Related Factor 2 / genetics
  • NF-E2-Related Factor 2 / metabolism
  • NF-kappa B / genetics
  • NF-kappa B / metabolism
  • Nervous System Diseases* / drug therapy
  • Nervous System Diseases* / etiology
  • Rats
  • Rats, Sprague-Dawley
  • Superoxide Dismutase-1 / genetics
  • Superoxide Dismutase-1 / metabolism

Substances

  • Antioxidants
  • Flavones
  • Heme Oxygenase-1
  • Matrix Metalloproteinase 9
  • Mmp9 protein, rat
  • NF-kappa B
  • nobiletin
  • Sod1 protein, rat
  • Superoxide Dismutase-1
  • NF-E2-Related Factor 2
  • Nfe2l2 protein, rat